--- schema_version: "secwatch.filing_event.v1" accession: "0001493152-23-029723" form_type: "8-K" ticker: "PPCB" cik: "0001517681" company_name: "Propanc Biopharma, Inc." filed_at: "2023-08-21T23:59:59+00:00" generated_at: "2026-06-11T06:09:31.064105+00:00" event_type: "debt" sentiment: "neutral" materiality_score: 0.5 calibrated_materiality_score: 0.5 confidence: "high" source: SEC EDGAR --- # Propanc Biopharma enters $55K convertible note and $132K promissory note financings ## Summary - Issued $55,000 convertible promissory note to 1800 Diagonal Lending LLC, convertible at 65% of market price after 180 days, 8% interest, matures Aug 16, 2024. - Issued $132,000 face (10% OID) promissory note for $120,000 proceeds, 10% interest, matures Nov 15, 2023; prepayable at 110%-130% premium. - Proceeds from both notes will be used for general working capital; notes issued under Section 4(a)(2) and Rule 506 private placement exemptions. - Convertible note includes prepayment options with escalating premiums (110% to 129% within 180 days) and default triggers 150% acceleration. - Promissory note default interest increases to 18%; Company must maintain corporate existence and cannot sell substantially all assets without consent. ## SEC filing metadata - accession: 0001493152-23-029723 - form_type: 8-K - ticker: PPCB - cik: 0001517681 - company_name: Propanc Biopharma, Inc. - filed_at: 2023-08-21T23:59:59+00:00 - event_type: debt - sentiment: neutral - materiality_score: 0.5 - calibrated_materiality_score: 0.5 - confidence: high - sec_items: 1.01, 2.03, 3.02, 9.01 - EDGAR index: https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/0001493152-23-029723-index.htm - EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/form8-k.htm ## Machine-readable alternates - HTML: https://secwatch.observer/filing/0001493152-23-029723 - JSON: https://secwatch.observer/filing/0001493152-23-029723.json - Plain text: https://secwatch.observer/filing/0001493152-23-029723.txt ## Key facts - Debt Financings Propanc Biopharma, Inc. incurred convertible notes of aggregate principal amount of $55,000 with August Investor at 8% per annum, which may be increased to 22% in the event of a default maturing August 16, 2024. - Instrument: convertible notes - Principal: aggregate principal amount of $55,000 - Counterparty: August Investor - Rate: 8% per annum, which may be increased to 22% in the event of a default - Maturity: August 16, 2024 - Event: incurrence source text: On August 16, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “August Investor”), which closed on August 16, 2023, pursuant to which the August Investor purchased a convertible promissory note (the “August Note”) from the Company in the aggregate principal amount of $55,000 evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/0001493152-23-029723-index.htm - Debt Financings Propanc Biopharma, Inc. incurred loan of principal face amount of $132,000 with August Lender at 10% per annum, which may be increased to 18% in the event of a default maturing November 15, 2023. - Instrument: loan - Principal: principal face amount of $132,000 - Counterparty: August Lender - Rate: 10% per annum, which may be increased to 18% in the event of a default - Maturity: November 15, 2023 - Event: incurrence source text: On August 15, 2023, the Company issued to an institutional investor (the “August Lender”) a 10% original issue discount promissory note (the “Promissory Note”) in consideration for $120,000, which has a principal face amount of $132,000, matures on November 15, 2023 and accrues interest at a rate of 10% per annum, which may be increased to 18% in the event of a default. evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/0001493152-23-029723-index.htm - Material Agreements Propanc Biopharma, Inc. entered into Promissory Note with an institutional investor (the “August Lender”) valued at $132,000 (effective 2023-08-15). - Action: entry - Agreement: notes offering - Counterparty: an institutional investor (the “August Lender”) - Value: $132,000 - Effective: 2023-08-15 source text: On August 15, 2023, the Company issued to an institutional investor (the “August Lender”) a 10% original issue discount promissory note (the “Promissory Note”) in consideration for $120,000, which has a principal face amount of $132,000 evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/0001493152-23-029723-index.htm - Material Agreements Propanc Biopharma, Inc. entered into Purchase Agreement with an investor (the “August Investor”) valued at $55,000 (effective 2023-08-16). - Action: entry - Agreement: equity purchase - Counterparty: an investor (the “August Investor”) - Value: $55,000 - Effective: 2023-08-16 source text: On August 16, 2023, Propanc Biopharma, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with an investor (the “August Investor”), which closed on August 16, 2023, pursuant to which the August Investor purchased a convertible promissory note (the “August Note”) from the Company in the aggregate principal amount of $55,000 evidence_url: https://www.sec.gov/Archives/edgar/data/1517681/000149315223029723/0001493152-23-029723-index.htm This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.